Interplay of angiotensin II and angiotensin(1-7) in the regulation of matrix metalloproteinases of human cardiocytes

Experimental Physiology

Volumn 93, Issue 5, 2008, Pages 599-612

  Pan, Chun Hsu ^a   Wen, Cheng Hao ^a   Lin, Chih Sheng ^a  

^a NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN[1-7]; GELATINASE A; GELATINASE B; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENZYME REGULATION; HEART MUSCLE CELL; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 42649117475     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2007.041830     Document Type: Article

References (59)

1. Allessie M, Ausma J & Schotten U (2002). Electrical, contractile and structural remodeling during atrial fibrillation. Cardiovasc Res 54, 230–246.
2. Batlle M, Perez‐Villa F, Garcia‐Pras E, Lazaro A, Orus J, Roque M & Roig E (2007). Down‐regulation of matrix metalloproteinase‐9 (MMP‐9) expression in the myocardium of congestive heart failure patients. Transplant Proc 39, 2344–2346.
3. Birkedal‐Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal‐Hansen B, DeCarlo A & Engler JA (1993). Matrix metalloproteinases: a review. Crit Rev Oral Biol Med 4, 197–250.
4. Brilla CG, Zhou G, Matsubara L & Weber KT (1994). Collagen metabolism in cultured adult rat cardiac fibroblasts: response to angiotensin II and aldosterone. J Mol Cell Cardiol 26, 809–820.
5. Brown RD, Jones GM, Laird RE, Hudson P & Long CS (2007). Cytokines regulate matrix metalloproteinases and migration in cardiac fibroblasts. Biochem Biophys Res Commun 362, 200–205.
6. Castoldi G, Di Gioia CR, Travaglini C, Busca G, Redaelli S, Bombardi C & Stella A (2007). Angiotensin II increases tissue‐specific inhibitor of metalloproteinase‐2 expression in rat aortic smooth muscle cells in vivo: evidence of a pressure‐independent effect. Clin Exp Pharmacol Physiol 34, 205–209.
7. Chen CL, Lin JL, Lai LP, Pan CH, Huang SKS & Lin CS (2007). Altered expression of FHL1, CARP, TSC‐22 and P311 provide insights into complex transcriptional regulation in pacing‐induced atrial fibrillation. Biochim Biophys Acta 1772, 317–329.
8. Chen K, Chen J, Li D, Zhang X & Mehta JL (2004). Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR‐γ ligand pioglitazone. Hypertension 44, 655–661.
9. Clark MA, Diz DI & Tallant EA (2001). Angiotensin‐(1–7) downregulates the angiotensin II type 1 receptor in vascular smooth muscle cells. Hypertension 37, 1141–1146.
10. Coker ML, Jolly JR, Joffs C, Etoh T, Holder JR, Bond BR & Spinale FG (2001). Matrix metalloproteinase expression and activity in isolated myocytes after neurohormonal stimulation. Am J Physiol Heart Circ Physiol 281, H543–H551.
11. Danielsen CC, Wiggers H & Andersen HR (1998). Increased amounts of collagenase and gelatinase in porcine myocardium following ischemia and reperfusion. J Mol Cell Cardiol 30, 1431–1442.
12. Denhardt DT, Feng B, Edwards DR, Cocuzzi ET & Malyankar UM (1993). Tissue inhibitor of metalloproteinases (TIMP, aka EPA): structure, control of expression and biological functions. Pharmacol Ther 59, 329–341.
13. Deschamps AM, Apple KA, Leonardi AH, McLean JE, Yarbrough WM, Stroud RE, Clark LL, Sample JA & Spinale FG (2005). Myocardial interstitial matrix metalloproteinase activity is altered by mechanical changes in LV load: interaction with the angiotensin type 1 receptor. Circ Res 96, 1110–1118.
14. Deschamps AM & Spinale FG (2005). Matrix modulation and heart failure: new concepts question old beliefs. Curr Opin Cardiol 20, 211–216.
15. Diez J (2007). Mechanisms of cardiac fibrosis in hypertension. J Clin Hypertens 9, 546–550.
16. Ferrario CM (1992). Biological roles of angiotensin‐(1–7). Hypertens Res 15, 61–66.
17. Ferrario CM, Chappell MC, Tallant EA, Brosnihan KB & Diz DI (1997). Counterregulatory actions of angiotensin‐(1–7). Hypertension 30, 535–541.
18. Ferreira AJ, Jacoby BA, Araujo CA, Macedo FA, Silva GAB, Almeida AP, Caliari MV & Santos RAS (2007a). The nonpeptide angiotensin‐(1–7) receptor Mas agonist AVE 0991 attenuates heart failure induced by myocardial infarction. Am J Physiol Heart Circ Physiol 292, H1113–H1119.
19. Ferreira AJ, Oliveira TL, Castro MC, Almeida AP, Castro CH, Caliari MV, Gava E, Kitten GT & Santos RAS (2007b). Isoproterenol‐induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin‐(1–7) analogue AVE 0991. Life Sci 81, 916–923.
20. Ferreira AJ & Santos RA (2005). Cardiovascular actions of angiotensin‐(1–7). Braz J Med Biol Res 38, 499–507.
21. Galis ZS & Khatri JJ (2002). Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90, 251–262.
22. Grobe JL, Mecca AP, Lingis M, Shenoy V, Bolton TA, Machado JM, Speth RC, Raizada MK & Katovich M (2007). Prevention of angiotensin II‐induced cardiac remodeling by angiotensin‐(1–7). Am J Physiol Heart Circ Physiol 292, H736–H742.
23. Grobe JL, Mecca AP, Mao H & Katovich MJ (2006). Chronic angiotensin‐(1–7) prevents cardiac fibrosis in DOCA‐salt model of hypertension. Am J Physiol Heart Circ Physiol 290, H2417–H2423.
24. Gunja‐Smith Z, Morales AR, Romanelli R & Woessner JF Jr (1996). Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Role of metalloproteinases and pyridinoline cross‐links. Am J Pathol 148, 1639–1648.
25. Iwata M, Cowling RT, Gurantz D, Moore C, Zhang S, Yuan JX & Greenberg BH (2005). Angiotensin‐(1–7) binds to specific receptors on cardiac fibroblasts to initiate anti‐fibrotic and anti‐trophic effects. Am J Physiol Heart Circ Physiol 289, H2356–H2363.
26. Li YY, Feldman AM, Sun Y & McTiernan CF (1998). Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 98, 1728–1734.
27. Lin CS, Lai LP, Lin JL, Sun YL, Hsu CW, Chen CL, Mao SJT & Huang SKS (2007). Increased expression of extracellular matrix proteins in rapid atrial pacing‐induced atrial fibrillation. Heart Rhythm 4, 938–949.
28. McEwan PE, Gray GA, Sherry L, Webb DJ & Kenyon CJ (1998). Differential effects of angiotensin II on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo. Circulation 98, 2765–2773.
29. Machado RD, Santos RA & Andrade SP (2001). Mechanisms of angiotensin‐(1–7)‐induced inhibition of angiogenesis. Am J Physiol Regul Integr Comp Physiol 280, R994–1000.
30. Mukherjee R, Herron AR, Lowry AS, Stroud RE, Stroud MR, Wharton JM, Ikonomidis JS, Crumbley AJ 3rd, Spinale FG & Gold MR (2006). Selective induction of matrix metalloproteinases and tissue inhibitor of metalloproteinases in atrial and ventricular myocardium in patients with atrial fibrillation. Am J Cardiol 97, 532–537.
31. Murphy G, Willenbrock F, Crabbe T, O'Shea M, Ward R, Atkinson S, O'Connell J & Docherty A (1994). Regulation of matrix metalloproteinase activity. Ann N Y Acad Sci 732, 31–41.
32. Nagase H & Woessner JF Jr (1999). Matrix metalloproteinases. J Biol Chem 274, 21491–21494.
33. Nakano Y, Niida S, Dote K, Takenaka S, Hirao H, Miura F, Ishida M, Shingu T, Sueda T, Yoshizumi M & Chayama K (2004). Matrix metalloproteinase‐9 contributes to human atrial remodeling during atrial fibrillation. J Am Coll Cardiol 43, 818–825.
34. Ohkubo N, Matsubara H, Nozawa Y, Mori Y, Murasawa S, Kijima K, Maruyama K, Masaki H, Tsutumi Y, Shibazaki Y, Iwasaka T & Inada M (1997). Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 96, 3954–3962.
35. Pan CH, Lin JL, Lai LP, Chen CL, Huang SKS & Lin CS (2007). Downregulation of angiotensin converting enzyme II is associated with pacing‐induced sustained atrial fibrillation. FEBS Lett 581, 526–534.
36. Papakonstantinou E, Roth M, Kokkas B, Papadopoulos C & Karakiulakis G (2001). Losartan inhibits the angiotensin II‐induced modifications on fibrinolysis and matrix deposition by primary human vascular smooth muscle cells. J Cardiovasc Pharmacol 38, 715–728.
37. Peng J, Gurantz D, Tran V, Cowling RT & Greenberg BH (2002). Tumor necrosis factor‐α‐induced AT 1 receptor upregulation enhances angiotensin II‐mediated cardiac fibroblast responses that favor fibrosis. Circ Res 91, 1119–1126.
38. Peterson JT, Li H, Dillon L & Bryant JW (2000). Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res 46, 307–315.
39. Regitz‐Zagrosek V, Fielitz J & Fleck E (1998). Myocardial angiotensin receptors in human hearts. Basic Res Cardiol 93 (Suppl. 2), 37–42.
40. Rouet‐Benzineb P, Gontero B, Dreyfus P & Lafuma C (2000). Angiotensin II induces nuclear factor‐κB activation in cultured neonatal rat cardiomyocytes through protein kinase C signaling pathway. J Mol Cell Cardiol 32, 1767–1778.
41. Santos RA, Campagnole‐Santos MJ & Andrade SP (2000). Angiotensin‐(1–7): an update. Regul Pept 91, 45–62.
42. Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, De Buhr I, Heringer‐Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole‐Santos MJ, Schultheiss HP, Speth R & Walther T (2003). Angiotensin‐(1–7) is an endogenous ligand for the G protein‐coupled receptor Mas. Proc Natl Acad Sci USA 100, 8258–8263.
43. Santos RAS, Castro CH, Gava E, Pinheiro SVB, Almeida AP, Paula RD, Cruz JS, Ramos AS, Rosa KT, Irigoyen MC, Bader M, Alenina N, Kitten GT & Ferreira AJ (2006). Impairment of in vitro and in vivo heart function in angiotensin‐(1–7) receptor Mas knockout mice. Hypertension 47, 996–1002.
44. Schwartzkopff B, Fassbach M, Pelzer B, Brehm M & Strauer BE (2002). Elevated serum markers of collagen degradation in patients with mild to moderate dilated cardiomyopathy. Eur J Heart Fail 4, 439–434.
45. Spach MS, Heidlage JF, Barr RC & Dolber PC (2004). Cell size and communication: role in structural and electrical development and remodeling of the heart. Heart Rhythm 1, 500–515.
46. Spinale FG (2002). Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ Res 90, 520–530.
47. Spinale FG, Coker ML, Heung LJ, Bond BR, Gunasinghe HR, Etoh T, Goldberg AT, Zellner JL & Crumbley AJ (2000). A matrix metalloproteinase induction/activation system exists in the human left ventricular myocardium and is upregulated in heart failure. Circulation 102, 1944–1949.
48. Stacy LB, Yu Q, Horak K & Larson DF (2007). Effect of angiotensin II on primary cardiac fibroblast matrix metalloproteinase activities. Perfusion 22, 51–55.
49. Sternlicht MD & Werb Z (2001). How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17, 463–516.
50. Studer R, Reinecke H, Muller B, Holtz J, Just H & Drexler H (1994). Increased angiotensin‐I converting enzyme gene expression in the failing human heart. Quantification by competitive RNA polymerase chain reaction. J Clin Invest 94, 301–310.
51. Su Z, Zimpelmann J & Burns KD (2006). Angiotensin‐(1–7) inhibits angiotensin II‐stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney Int 69, 2212–2218.
52. Tallant EA & Clark MA (2003). Molecular mechanisms of inhibition of vascular growth by angiotensin‐(1–7). Hypertension 42, 574–579.
53. Taniyama Y, Morishita R, Nakagami H, Moriguchi A, Sakonjo H, Shokei K, Matsumoto K, Nakamura T, Higaki J & Ogihara T (2000). Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters. Circulation 102, 246–252.
54. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AJ 3rd & Spinale FG (1998). Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end‐stage dilated cardiomyopathy. Circulation 97, 1708–1715.
55. Ward RV, Atkinson SJ, Slocombe PM, Docherty AJ, Reynolds JJ & Murphy G (1991). Tissue inhibitor of metalloproteinases‐2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes. Biochim Biophys Acta 1079, 242–246.
56. Wilson EM, Gunasinghe HR, Coker ML, Sprunger P, Lee‐Jackson D, Bozkurt B, Deswal A, Mann DL & Spinale FG (2002). Plasma matrix metalloproteinase and inhibitor profiles in patients with heart failure. J Card Fail 8, 390–398.
57. Xie Z, Singh M & Singh K (2004). Differential regulation of matrix metalloproteinase‐2 and ‐9 expression and activity in adult rat cardiac fibroblasts in response to interleukin‐1β. J Biol Chem 279, 39513–39519.
58. Zhu H, Zhang W, Guo CH, Zhang G, Zhang WD, Zhong M, Yang GR, Ge ZM & Zhang Y (2005). Effects of matrix metalloproteinase‐9 and tissue inhibitor‐1 of metalloproteinase expression on atrial structural remodeling during chronic atrial fibrillation. [in Chinese]Zhonghua Yi Xue Za Zhi 85, 45–48.
59. Zhu Z, Zhong J, Zhu S, Liu D, Van Der Giet M & Tepel M (2002). Angiotensin‐(1–7) inhibits angiotensin II‐induced signal transduction. J Cardiovasc Pharmacol 40, 693–700.